Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://www.ncbi.nlm.nih.gov/pubmed/27746425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://www.ncbi.nlm.nih.gov/pubmed/27746425

Ejemplares similares